Nkarta公司宣布已与美国食品药品监督管理局（FDA）就Nkx019用于治疗自身免疫疾病的门诊给药方案达成协议。这一关键进展将显著提升该疗法的可及性，使其得以更广泛地应用于社区风湿病中心，为更多患者提供便利。
Nkarta公司宣布已与美国食品药品监督管理局（FDA）就Nkx019用于治疗自身免疫疾病的门诊给药方案达成协议。这一关键进展将显著提升该疗法的可及性，使其得以更广泛地应用于社区风湿病中心，为更多患者提供便利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.